Foundation to share insights from diabetes report on children and young people at ISPAD 2025

With global cases of type 1 diabetes (T1D) among children and young people (CYP) on the rise, and the World Health Organization’s 2030 targets for improving diabetes care approaching, improving access to essential diabetes care products worldwide is more crucial than ever. 

In November, leaders from the pharmaceutical industry and the diabetes research community will convene in Montreal for the International Society for Pediatric and Adole­scent Diabetes (IPSAD) to discuss the advancement of diabetes care and research, especially relating to the lives of children and families living with diabetes. 

Representing the Access to Medicine Foundation, Research Coordinator Emma Schiffman will attend the conference to share findings of the Diabetes Programme’s most recent research report 'Access to diabetes care for children and young people: Pharma companies' current actions and opportunities ahead', published in May. The report analysed the pharmaceutical industry’s efforts to provide access to critical T1D care products in underserved regions, where many CYP lack access to essential care.  

A display showcasing key insights from the report will highlight the important role the pharmaceutical industry plays in the diabetes care supply chain, and the necessary next steps that companies must take to address persistent gaps in care in low- and middle-income countries.

About ISPAD 2025

The International Society for Pediatric and Adolescent Diabetes (ISPAD) is a global organisation dedicated to the advancement of diabetes care, research and education for children and adolescents. In 2025, ISPAD will hold its 51st Annual Conference in Montreal, Canada, convening members of the global pediatric diabetes community including healthcare professionals, researchers, and educators to share knowledge and advance care for young people living with diabetes worldwide.